

Year in Review: Clinical Investigators Provide Perspectives on the Most Relevant New Publications, Data Sets and Advances in Targeted Therapy for Lung Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which disease-free survival result was demonstrated in the Phase III ADAURA trial evaluating osimertinib versus placebo as adjuvant therapy after complete tumor resection for patients with early-stage non-small cell lung cancer (NSCLC) with EGFR mutations?**
  - a. A statistically significant and clinically meaningful benefit with adjuvant osimertinib**
  - b. No statistically significant or clinically meaningful benefit with adjuvant osimertinib
- 2. Which of the following conditions has been reported as an adverse event of special interest in patients with NSCLC with HER2 mutations receiving trastuzumab deruxtecan?**
  - a. New secondary cancer
  - b. Ocular toxicities
  - c. Interstitial lung disease**
- 3. Which of the following drug types best describes the mechanism of action of the recently FDA-approved agent selpercatinib for patients with metastatic NSCLC?**
  - a. ALK inhibitor
  - b. EGFR inhibitor
  - c. HER2 inhibitor
  - d. MET inhibitor
  - e. RET inhibitor**
  - f. ROS1 inhibitor
- 4. Capmatinib was recently FDA approved for patients with metastatic NSCLC with which of the following genomic alterations?**
  - a. EGFR mutations
  - b. RET fusions
  - c. MET exon 14 skipping mutations**